Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17789645 | 0.93 | SMN1; SMN2 (0.54) | TP53SMN1; SMN2HRH3POLBGAA | |
| SCHEMBL10232853 | 0.89 | TP53 (0.47) | TP53SMN1; SMN2HRH3POLBGAA | |
| SCHEMBL23396158 | 0.82 | HRH3 (0.50) | TP53SMN1; SMN2HRH3POLBALDH1A1 | |
| SCHEMBL22849908 | 0.82 | HRH3 (0.50) | TP53SMN1; SMN2HRH3POLBALDH1A1 | |
| SCHEMBL24219800 | 0.82 | HRH3 (0.50) | TP53SMN1; SMN2HRH3ALDH1A1MAPT | |
| SCHEMBL25872140 | 0.81 | HRH3 (0.49) | TP53HRH3MAPT | |
| SCHEMBL18713111 | 0.79 | SMN1; SMN2 (0.45) | TP53SMN1; SMN2HRH3GAAALDH1A1 | |
| SCHEMBL741956 | 0.79 | MAPT (0.61) | GAAALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL28998853 | 0.79 | TP53 (0.50) | TP53SMN1; SMN2POLBGAAALDH1A1 | |
| SCHEMBL15159100 | 0.79 | HRH3 (0.77) | TP53SMN1; SMN2HRH3ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109311889-A | Activin receptor-like kinase inhibitors | 蓝图药品公司 | 2019-02-05 | — | — | CN | claimed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240208993-A1 | FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-20230295145-A1 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | GENENTECH INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295145-A1 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | GENENTECH INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20090118269-A1 | Methods for Treating Spinal Muscular Atrophy Using Tetracycline Compounds | PARATEK PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090099158-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-16 | — | — | US | disclosed |
| WO-2008109336-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-12 | — | — | WO | disclosed |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-7250444-B2 | Pyrrole-based HMG-CoA reductase inhibitors | PFIZER INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250444-B2 | Pyrrole-based HMG-CoA reductase inhibitors | PFIZER INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118269-A1 | Methods for Treating Spinal Muscular Atrophy Using Tetracycline Compounds | SMN1; SMN2, MTPN, TUBB2A | TP53 4871/4885SMN1; SMN2 1/4885HRH3 3581/4885 |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | TP53 1637/4885SMN1; SMN2 4707/4885HRH3 3552/4885 |
| US-20090099158-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | TP53 4445/4885SMN1; SMN2 4327/4885HRH3 1/4885 |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | TP53 4040/4885SMN1; SMN2 4174/4885HRH3 3788/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | TP53 1637/4885SMN1; SMN2 4707/4885HRH3 3552/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | TP53 503/4885SMN1; SMN2 2633/4885HRH3 994/4885 |
| US-20230295145-A1 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | DPYD, TP53, GLS | TP53 2/4885SMN1; SMN2 2183/4885HRH3 3789/4885 |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | TP53 3310/4885SMN1; SMN2 4377/4885HRH3 2176/4885 |
| US-20070197628-A1 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | TP53 4875/4885SMN1; SMN2 2106/4885HRH3 779/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | TP53 503/4885SMN1; SMN2 2633/4885HRH3 994/4885 |
| US-20240208993-A1 | FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | IRAK4, FLT3, IRAK2 | TP53 1488/4885SMN1; SMN2 4451/4885HRH3 3531/4885 |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | TP53 4040/4885SMN1; SMN2 4174/4885HRH3 3788/4885 |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | KDM1A, TET1, KDM3A | TP53 2286/4885SMN1; SMN2 1994/4885HRH3 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.